You just read:

OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis

News provided by

OncoGenex Pharmaceuticals, Inc.

May 30, 2015, 02:15 ET